GET DAILY SIGNALSPurple Biotech (PPBT) Gains +73% Over 30 Days on CAPTN-3 Patent News
Key Takeaways
- Purple Biotech (PPBT) has climbed roughly 73% over the trailing 30 days, from about $1.47 in early August to around $2.55.
- A U.S. patent Notice of Allowance covering tri-specific antibody designs from its CAPTN-3 platform was the primary catalyst, triggering unusually heavy trading volume.
- New preclinical data on lead candidate IM1240 and a manufacturing milestone have reinforced investor interest in the platform.
- The stock remains far below year-ago levels and is still down over the trailing quarter despite the sharp rebound.
- Purple Biotech is pre-revenue, with roughly $6.1 million in cash as of June 30, 2026, funding operations into mid-2027.
Purple Biotech (PPBT) Company Overview and Market Position
Purple Biotech Ltd. is a clinical-stage oncology company based in Rehovot, Israel, focused on next-generation immunotherapies that aim to address tumor immune evasion and drug resistance. Its CAPTN-3 platform features “capped” tri-specific antibodies that target tumor cells while engaging both T cells and natural killer (NK) cells. The lead candidate, IM1240, is moving toward clinical development, while IM1305 remains in preclinical studies.
The broader pipeline includes CM24, a CEACAM1-blocking antibody that showed improved outcomes across efficacy endpoints in a Phase 2 pancreatic cancer trial, and NT219, a dual IRS1/2 and STAT3 inhibitor in Phase 2 for recurrent or metastatic head and neck cancer. As a pre-revenue micro-cap, Purple Biotech represents a high-risk, high-reward profile where pipeline progress and funding capacity shape investor focus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Purple Biotech (PPBT) Stock Price Performance: Last 30 Days vs. Quarter
Over the past 30 days, PPBT shares have moved from roughly $1.47 to approximately $2.55, representing a gain of about 73%. The advance occurred in a handful of high-volume sessions tied to company-specific developments rather than a steady upward trend.
Looking at the full quarter, the picture is more mixed. From roughly $2.95 in early June, shares fell to about $1.66 by the start of September — a decline of approximately 44% — before the recent rally reduced those losses. The 30-day advance therefore reflects a sharp, news-driven rebound within a longer-term downtrend, and the stock continues to trade well below year-ago levels.
What Drove PPBT Stock Price in the Last 30 Days
The main catalyst came from a patent update. The U.S. Patent and Trademark Office issued a Notice of Allowance for a patent covering tri-specific antibody designs and their uses within the CAPTN-3 platform. Management noted that the allowance strengthens protection for the platform’s modular design, which supports swapping tumor-targeting and functional components to create new multispecific candidates. The news sparked unusually heavy volume, with tens of millions of shares trading compared with a typical average in the tens of thousands.
Additional support came from second-quarter 2026 results released on August 7, which included new preclinical data for IM1240 and updates on the CAPTN-3 platform, along with a separate manufacturing milestone for IM1240. On the analyst front, H.C. Wainwright kept a Buy rating but reduced its price target from $30 to $17, citing a low cash balance and higher operating expenses. The combination of positive pipeline developments, a thin float, and speculative interest amplified the move higher.
What Drove PPBT Stock Performance Over the Last Quarter
The broader quarterly trend reflected structural and balance-sheet pressures more than pipeline news. In early March 2026, Purple Biotech completed a one-for-ten reverse split of its American Depositary Shares to regain compliance with Nasdaq’s $1.00 minimum bid price requirement. While such actions are technical and do not alter underlying value, they often occur amid listing or funding challenges.
Throughout the quarter, shares continued to decline as investors focused on a shrinking cash position and the prospect of future dilution. The company reported roughly $6.1 million in cash as of June 30, 2026, expected to fund operations only into mid-2027. That financing overhang, together with broader weakness among small- and micro-cap pre-revenue biotech names, kept the stock in a downtrend until the late-quarter patent and data catalysts triggered the rebound.
PPBT Stock Forecast Drivers: What Investors Should Watch Next
Several elements are likely to influence Purple Biotech’s stock in the periods ahead. The most critical is progress on IM1240 toward a first-in-human Phase 1 trial, which management has targeted for 2027 and made dependent on securing a partnership or additional financing. Further preclinical data readouts from IM1240 and IM1305 are anticipated through 2026 and could provide ongoing catalysts.
Investors should also track the company’s cash runway and any capital-raising activity given the roughly $6.1 million cash balance. Maintaining Nasdaq listing compliance, formal issuance of the newly allowed patent, and the next quarterly earnings report remain key milestones. Because Purple Biotech is pre-revenue, clinical, regulatory, and financing outcomes — rather than sales or earnings growth — will continue to drive valuation. As with any early-stage biotech, these developments carry substantial uncertainty and should be considered within a broader, diversified investment approach. From what I see, these milestones will be worth monitoring closely.
Using AI Tools for Market Context
When evaluating momentum across broader markets, I often review Tickeron’s Trending AI Robots page. It offers a curated look at automated trading strategies that monitor thousands of tickers, highlighting only the top-performing and most relevant bots. These strategies differ in approach, holding periods, and performance metrics, providing a useful way to compare data-driven signals alongside fundamental research. The section helps identify patterns that may align with or contrast one’s own analysis without serving as a direct recommendation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PPBT's Stochastic Oscillator is sitting in overbought zone for 4 days
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PPBT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for PPBT entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PPBT's RSI Oscillator exited the oversold zone, 45 of 53 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on PPBT as a result. In 60 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for PPBT just turned positive on October 30, 2026. Looking at past instances where PPBT's MACD turned positive, the stock continued to rise in 29 of 44 cases over the following month. The odds of a continued upward trend are 66%.
Following a +7.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where PPBT advanced for three days, in 169 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
PPBT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.172) is normal, around the industry mean (3.498). P/E Ratio (-0.027) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. PPBT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PPBT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of pharmaceutical drug discovery and development services
Industry Biotechnology
Advertisement